BUSINESS

Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show

January 28, 2019
Shionogi’s single-dose influenza drug Xofluza (baloxavir marboxil) grabbed a volume-based share of 47% in the Japanese flu drug market in October-December 2018, outdistancing the pack of rivals including last season’s top-seller Inavir (laninamivir), according to a Jiho tally of health…

To read the full story

Related Article

BUSINESS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…